Literature DB >> 15752840

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.

Aaron P Miles1, Holly A McClellan, Kelly M Rausch, Daming Zhu, Michael D Whitmore, Sanjay Singh, Laura B Martin, Yimin Wu, Birgitte K Giersing, Anthony W Stowers, Carole A Long, Allan Saul.   

Abstract

Montanide ISA 720 is an experimental adjuvant, formulated as water-in-oil emulsions, that induces high antibody titers in several animal species. It has been used in human vaccine trials with malaria and HIV vaccines. The heightened response is likely due, in part, to the formation of a depot at the injection site. However, post-formulation modifications were seen with seven proteins tested during storage of ISA 720 formulations at 37 degrees C for 1 week and two proteins stored longer at 4 degrees C. Potency studies in mice, in which the stored vaccines were diluted into placebo emulsions for appropriate dosing, indicated that this instability could lead to loss of immunogenicity in the post-injection depot, limiting the allowable storage time of preformed vaccines. We describe point-of-injection formulation for ISA 720 vaccines that meets the requirement for in vitro stability. For preformed vaccines, addition of glycine or glycylglycine prevented antigen modification on storage at 37 degrees C, providing a potential way of stabilizing antigen/ISA 720 formulations for in vitro storage and the post-injection depot.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752840     DOI: 10.1016/j.vaccine.2004.08.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

2.  Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.

Authors:  Tanios Bekaii-Saab; Robert Wesolowski; Daniel H Ahn; Christina Wu; Amir Mortazavi; Maryam Lustberg; Bhuvaneswari Ramaswamy; Jeffrey Fowler; Lai Wei; Jay Overholser; Pravin T P Kaumaya
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

Review 3.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

5.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

6.  Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

Authors:  Daming Zhu; Holly McClellan; Weili Dai; Elizabeth Gebregeorgis; Mary Anne Kidwell; Joan Aebig; Kelly M Rausch; Laura B Martin; Ruth D Ellis; Louis Miller; Yimin Wu
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

7.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

8.  Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Authors:  Caroline Othoro; Dean Johnston; Rebecca Lee; Jonathan Soverow; Jean-Claude Bystryn; Elizabeth Nardin
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

9.  Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

Authors:  Bo Jin; Richard Y Wang; Qi Qiu; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

10.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.